Black Swift Group LLC Sells 33,500 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Black Swift Group LLC trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 87.0% during the fourth quarter, HoldingsChannel reports. The fund owned 5,000 shares of the company’s stock after selling 33,500 shares during the quarter. Black Swift Group LLC’s holdings in TransMedics Group were worth $312,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Arizona State Retirement System grew its holdings in TransMedics Group by 1.9% during the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company’s stock worth $603,000 after acquiring an additional 184 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in shares of TransMedics Group by 33.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after purchasing an additional 219 shares during the last quarter. National Bank of Canada FI boosted its stake in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares during the last quarter. Quarry LP boosted its stake in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

TMDX opened at $67.44 on Thursday. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company’s fifty day moving average price is $68.12 and its two-hundred day moving average price is $99.12. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a market cap of $2.27 billion, a price-to-earnings ratio of 71.75 and a beta of 2.12.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TMDX. Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Piper Sandler cut their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Oppenheimer reissued an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, Robert W. Baird cut their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.